Apogee Therapeutics, Inc. (APGE)

NASDAQ: APGE · Real-Time Price · USD

71.90

-1.61 (-2.19%)

At close: Mar 13, 2026, 4:00 PM EDT

72.60

+0.70 (0.97%)

Pre-market: Mar 16, 2026, 8:20 AM EDT

Apogee Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-255.84	-182.15	-83.99
Depreciation & Amortization	1.42	0.19	-
Stock-Based Compensation	46.28	23.33	6.1
Other Adjustments	-3.82	-10.55	-2.98
Changes in Accounts Payable	0.15	-1.07	1.61
Changes in Accrued Expenses	-1.07	6.29	7.65
Changes in Other Operating Activities	-14.55	-7.22	-3.16
Operating Cash Flow	-227.45	-171.17	-74.76
Capital Expenditures	-5.15	-1.15	-0.17
Purchases of Investments	-642.3	-649.45	-303.74
Proceeds from Sale of Investments	467.87	350.14	30
Investing Cash Flow	-179.57	-300.46	-273.91
Issuance of Common Stock	396.49	495.11	315.39
Net Common Stock Issued (Repurchased)	396.49	495.11	315.39
Financing Cash Flow	396.49	495.11	315.39
Net Cash Flow	-10.53	23.47	-33.28
Free Cash Flow	-232.6	-172.33	-74.93
Free Cash Flow Per Share	-3.83	-3.12	-3.00
Levered Free Cash Flow	-275.05	-185.11	-78.05
Unlevered Free Cash Flow	-304.49	-219.81	-87.07

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q